María de Los Angeles Nava Castañeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María de Los Angeles Nava Castañeda has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Diana Cristina Navarro Rodríguez
Instituto Mexicano del Seguro Social
1 shared publication - Dulce Samantha Ortíz Fonseca
Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No.55, Culiacán, Sinaloa, México
1 shared publication - Gabriela del Carmen Angulo Trizón
Universidad Autónoma de Sinaloa, Facultad de Enfermería Culiacán Sinaloa, México
1 shared publication - Hermilia Páez Gámez
Universidad Autónoma de Sinaloa, Facultad de Enfermería Culiacán Sinaloa, México
1 shared publication - Irene Estefanye Jimenez Leyva
Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No.55, Culiacán, Sinaloa, México
1 shared publication - Júlio Manuel Medina Serrano
Instituto Mexicano del Seguro Social, Organo de Operación Administrativa Desconcentrada en Sinaloa, Coordinación de Planeación y Enlace Institucional, Culiacán Sinaloa México
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 5, 1095
Impact of phytoestrogen use on the quality of life of perimenopausal or postmenopausal women in Sinaloa, Mexico
Introduction: menopause causes clinical symptoms that significantly impact women’s quality of life. Phytoestrogens, such as soy isoflavones, have been studied as treatment for climacteric syndrome, showing improvements in vasomotor and psychological symptoms.Objective: to determine the impact of the use of phytoestrogens (soy isoflavones) on the quality of life of women with perimenopause or postmenopause at Family Medicine Unit No. 55 of the Mexican Social Security Institute in Culiacán, Sinaloa, Mexico. Method: a randomized clinical trial was conducted with 44 women aged 45 to 60 with climacteric symptoms. Participants were assigned to an experimental group (EG), which received 50 mg of soy isoflavones every 24 hours, and a control group (CG), which received a placebo for 12 weeks. The Menopause Rating Scale was applied before and after the intervention to evaluate somatic, psychological, and urogenital symptoms. Descriptive and inferential statistics were used. Results: supplementation with soy isoflavones in the EG showed significant improvements in overall quality of life (Cohen d = 1,54), as well as in the somatic (d = 1,52) and psychological (d = 1,10) subscales, indicating a large effect (d > 0,80). However, the urogenital dimension showed no significant effect (d = 0). The CG experienced a significant deterioration in these subscales. Conclusions: soy isoflavones significantly improved the quality of life of women in perimenopause and postmenopause in the somatic and psychological dimensions, showing a large effect. No changes were observed in the urogenital dimension
- 1 January 2025
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 5, 1095
Open AccessImpact of phytoestrogen use on the quality of life of perimenopausal or postmenopausal women in Sinaloa, Mexico
Introduction: menopause causes clinical symptoms that significantly impact women’s quality of life. Phytoestrogens, such as soy isoflavones, have been studied as treatment for climacteric syndrome, showing improvements in vasomotor and psychological symptoms.Objective: to determine the impact of the use of phytoestrogens (soy isoflavones) on the quality of life of women with perimenopause or postmenopause at Family Medicine Unit No. 55 of the Mexican Social Security Institute in Culiacán, Sinaloa, Mexico. Method: a randomized clinical trial was conducted with 44 women aged 45 to 60 with climacteric symptoms. Participants were assigned to an experimental group (EG), which received 50 mg of soy isoflavones every 24 hours, and a control group (CG), which received a placebo for 12 weeks. The Menopause Rating Scale was applied before and after the intervention to evaluate somatic, psychological, and urogenital symptoms. Descriptive and inferential statistics were used. Results: supplementation with soy isoflavones in the EG showed significant improvements in overall quality of life (Cohen d = 1,54), as well as in the somatic (d = 1,52) and psychological (d = 1,10) subscales, indicating a large effect (d > 0,80). However, the urogenital dimension showed no significant effect (d = 0). The CG experienced a significant deterioration in these subscales. Conclusions: soy isoflavones significantly improved the quality of life of women in perimenopause and postmenopause in the somatic and psychological dimensions, showing a large effect. No changes were observed in the urogenital dimension